Home

BVF Partners OS Ltd.

CIK 1660684 · last filed 2025-08-07

BVF Partners OS Ltd. is a corporate insider who has filed 17 SEC Form 4 insider transactions across 13 companies since 2017. The most recent filing, for EPIX, was dated Aug 7, 2025. Across all open-market trades the lifetime net is −$771.2M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $448.9M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$448.94M

Companies

13

Total Filings

17

Lifetime Open-Market Net

-$771.20M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
ESSA Pharma Inc. (EPIX) Delisted 4,726,809 $0.20 $951.0K -$2.9K 1 2025-08-07
ELDN 145,029 $3.40 $493.1K $0 1 2023-05-09
CTI BIOPHARMA CORP (CTIC) Delisted Director 62,978 $9.09 $572.5K -$520.20M 1 2022-08-11
Merus N.V. (MRUS) Delisted 311,210 $90.00 $28.01M -$432.55M 2 2021-07-07
Eledon Pharmaceuticals, Inc. (NVUS) Delisted 771,780 — — $0 1 2020-12-28
OLMA 3,392,663 $11.62 $39.42M $215.71M 1 2020-11-20
XOMA 1,941,035 $40.17 $77.97M $5.47M 1 2020-08-25
KYMR 1,359,109 $106.16 $144.28M $0 1 2020-08-25
CYTK 2,350,829 $79.45 $186.77M -$118.47M 1 2020-02-18
FIVE PRIME THERAPEUTICS, INC. (FPRX) Delisted 3,648,474 $38.00 $138.64M $30.45M 2 2019-12-11
INFINITY PHARMACEUTICALS, INC. (INFI) Delisted 5,815,887 $0.04 $260.0K $8.55M 1 2018-11-15
CONCERT PHARMACEUTICALS, INC. (CNCE) Delisted 291,788 $8.37 $2.44M $36.80M 1 2017-10-23
ALPINE IMMUNE SCIENCES, INC. (NVLS) Delisted 163,342 — — $3.04M 2 2017-05-19

Recent Filings

17 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2025-08-07 ESSA Pharma Inc. (EPIX) Delisted Mixed +29,198,440 -$10 EDGAR
2023-05-09 ELDN Buy (P) +19,789,320 $0 EDGAR
2022-08-11 CTI BIOPHARMA CORP (CTIC) Delisted Mixed −1,166,690 -$520.20M EDGAR
2021-07-07 Merus N.V. (MRUS) Delisted Sell (S) −21,860,220 -$453.60M EDGAR
2020-12-28 Eledon Pharmaceuticals, Inc. (NVUS) Delisted Conv (C) +12,896,280 $0 EDGAR
2020-11-20 OLMA Mixed +63,520,100 $215.71M EDGAR
2020-09-14 Merus N.V. (MRUS) Delisted Buy (P) +1,896,510 $21.05M EDGAR
2020-08-25 XOMA Buy (P) +281,750 $5.47M EDGAR
2020-08-25 KYMR Mixed +25,574,970 $195.74M EDGAR
2020-02-18 CYTK Sell (S) −7,504,210 -$118.47M EDGAR
Showing 1–10 of 17
Page 1 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.